Financiële vergelijkingen Achilles Therapeutics plc
Aandelen
ACHL
US00449L1026
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,380 USD | 0,00% |
|
-0,36% | +21,49% |
05/02 | Syncona portefeuillebedrijf Achilles Therapeutics gaat over tot vrijwillige liquidatie | MT |
04/02 | Sergio Quezada stapt op als Chief Scientific Officer van Achilles Therapeutics plc | CI |
Toevoegen aan een lijst 0 geselecteerde | Omzet (N-1) | Nettomarge (N-1) | Ebit-marge (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | |
---|---|---|---|---|---|---|---|
9,87 mld. | 36,68% | 44,33% | 22,99% | 17,71% | -2.46x | ||
14,2 mld. | 31,07% | 36,33% | 19,23% | 15,02% | -1.12x | ||
1,29 mld. | 23,26% | 33,51% | 8,54% | 7,69% | 10.14x | ||
4,22 mld. | 24,36% | 18,08% | 4,62% | 4,02% | -13.1x | ||
2,46 mld. | 35,86% | 49,12% | 22,26% | 14,47% | 2.05x | ||
5,69 mld. | 26,5% | 29,43% | 18,99% | 15,45% | -0.64x | ||
305 mln. | 245,59% | 232,51% | - | 50,2% | -0.8x | ||
2,99 mld. | 36,44% | 32,53% | 16,51% | 15,63% | -2.3x | ||
2,36 mld. | 14,49% | 24,22% | 23,66% | 20,82% | -2.74x | ||
2,4 mld. | 19,96% | 24,97% | 9,02% | 6,41% | -0.78x | ||
1,24 mld. | 43,11% | 21,54% | 86,15% | 1,86% | 1.96x | ||
2,17 mld. | 24,04% | 27,88% | 21,77% | 16,6% | -1.11x | ||
167 mln. | 12,22% | 37,48% | 3,46% | 2,93% | 11.91x | ||
295 mln. | 180,51% | 170,79% | 818,43% | 50,27% | -0.33x | ||
638 mln. | 44,81% | 45,26% | 55,36% | 27,64% | 0.65x | ||
Gemiddelde | 3,35 mld. | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | 0,09x | |
Gewogen gemiddelde per kap. | 6,77 mld. | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | percentage-no-prefix | -0,67x |
- Beurs
- Aandelen
- Koers ACHL
- Sector Achilles Therapeutics plc
- Financiële vergelijkingen